 | • レポートコード：GIR-2104Z12556 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、鎌状赤血球症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。鎌状赤血球症治療の種類別市場規模（鎌状赤血球貧血、鎌状ベータサラセミア、鎌状ヘモグロビンC病）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・鎌状赤血球症治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Eli Lilly、Novartis、Pfizer、Baxter、Emmaus Life Sciences、Bluebird bio、Blood Therapeutics、Sangamo Therapeutics、Acceleron Pharma、Arena Pharmaceuticals、Alnylam Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：鎌状赤血球貧血、鎌状ベータサラセミア、鎌状ヘモグロビンC病 ・用途別分析2016年-2026年：病院、診療所、その他 ・鎌状赤血球症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・鎌状赤血球症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・鎌状赤血球症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・鎌状赤血球症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・鎌状赤血球症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Sickle Cell Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Sickle Cell Disease Treatment size is estimated to be USD 2993.8 million in 2025 from USD 1975.8 million in 2019, with a change XX% between 2019 and 2020. The global Sickle Cell Disease Treatment market size is expected to grow at a CAGR of 10.9% for the next five years.
Market segmentation
Sickle Cell Disease Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
AstraZeneca
Eli Lilly
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird bio
Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Sickle Cell Disease Treatment
1.2 Classification of Sickle Cell Disease Treatment by Type
1.2.1 Overview: Global Sickle Cell Disease Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Sickle Cell Disease Treatment Revenue Market Share by Type in 2020
1.2.3 Sickle Cell Anemia
1.2.4 Sickle Beta Thalassemia
1.2.5 Sickle Hemoglobin C Disease
1.3 Global Sickle Cell Disease Treatment Market by Application
1.3.1 Overview: Global Sickle Cell Disease Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Sickle Cell Disease Treatment Market Size & Forecast
1.5 Global Sickle Cell Disease Treatment Market Size and Forecast by Region
1.5.1 Global Sickle Cell Disease Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Sickle Cell Disease Treatment Market Size by Region, (2016-2021)
1.5.3 North America Sickle Cell Disease Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Sickle Cell Disease Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Sickle Cell Disease Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Sickle Cell Disease Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Sickle Cell Disease Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Sickle Cell Disease Treatment Market Drivers
1.6.2 Sickle Cell Disease Treatment Market Restraints
1.6.3 Sickle Cell Disease Treatment Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Sickle Cell Disease Treatment Product and Solutions
2.1.4 AstraZeneca Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Sickle Cell Disease Treatment Product and Solutions
2.2.4 Eli Lilly Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Eli Lilly Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Sickle Cell Disease Treatment Product and Solutions
2.3.4 Novartis Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Sickle Cell Disease Treatment Product and Solutions
2.4.4 Pfizer Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Baxter
2.5.1 Baxter Details
2.5.2 Baxter Major Business
2.5.3 Baxter Sickle Cell Disease Treatment Product and Solutions
2.5.4 Baxter Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Baxter Recent Developments and Future Plans
2.6 Emmaus Life Sciences
2.6.1 Emmaus Life Sciences Details
2.6.2 Emmaus Life Sciences Major Business
2.6.3 Emmaus Life Sciences Sickle Cell Disease Treatment Product and Solutions
2.6.4 Emmaus Life Sciences Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Emmaus Life Sciences Recent Developments and Future Plans
2.7 Bluebird bio
2.7.1 Bluebird bio Details
2.7.2 Bluebird bio Major Business
2.7.3 Bluebird bio Sickle Cell Disease Treatment Product and Solutions
2.7.4 Bluebird bio Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bluebird bio Recent Developments and Future Plans
2.8 Blood Therapeutics
2.8.1 Blood Therapeutics Details
2.8.2 Blood Therapeutics Major Business
2.8.3 Blood Therapeutics Sickle Cell Disease Treatment Product and Solutions
2.8.4 Blood Therapeutics Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Blood Therapeutics Recent Developments and Future Plans
2.9 Sangamo Therapeutics
2.9.1 Sangamo Therapeutics Details
2.9.2 Sangamo Therapeutics Major Business
2.9.3 Sangamo Therapeutics Sickle Cell Disease Treatment Product and Solutions
2.9.4 Sangamo Therapeutics Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sangamo Therapeutics Recent Developments and Future Plans
2.10 Acceleron Pharma
2.10.1 Acceleron Pharma Details
2.10.2 Acceleron Pharma Major Business
2.10.3 Acceleron Pharma Sickle Cell Disease Treatment Product and Solutions
2.10.4 Acceleron Pharma Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Acceleron Pharma Recent Developments and Future Plans
2.11 Arena Pharmaceuticals
2.11.1 Arena Pharmaceuticals Details
2.11.2 Arena Pharmaceuticals Major Business
2.11.3 Arena Pharmaceuticals Sickle Cell Disease Treatment Product and Solutions
2.11.4 Arena Pharmaceuticals Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Arena Pharmaceuticals Recent Developments and Future Plans
2.12 Alnylam Pharmaceuticals
2.12.1 Alnylam Pharmaceuticals Details
2.12.2 Alnylam Pharmaceuticals Major Business
2.12.3 Alnylam Pharmaceuticals Sickle Cell Disease Treatment Product and Solutions
2.12.4 Alnylam Pharmaceuticals Sickle Cell Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Sickle Cell Disease Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Sickle Cell Disease Treatment Players Market Share
3.2.2 Top 10 Sickle Cell Disease Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Sickle Cell Disease Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Sickle Cell Disease Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Sickle Cell Disease Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Sickle Cell Disease Treatment Revenue Market Share by Application (2016-2021)
5.2 Sickle Cell Disease Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Sickle Cell Disease Treatment Revenue by Type (2016-2026)
6.2 North America Sickle Cell Disease Treatment Revenue by Application (2016-2026)
6.3 North America Sickle Cell Disease Treatment Market Size by Country
6.3.1 North America Sickle Cell Disease Treatment Revenue by Country (2016-2026)
6.3.2 United States Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Sickle Cell Disease Treatment Revenue by Type (2016-2026)
7.2 Europe Sickle Cell Disease Treatment Revenue by Application (2016-2026)
7.3 Europe Sickle Cell Disease Treatment Market Size by Country
7.3.1 Europe Sickle Cell Disease Treatment Revenue by Country (2016-2026)
7.3.2 Germany Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
7.3.3 France Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Sickle Cell Disease Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Sickle Cell Disease Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Sickle Cell Disease Treatment Market Size by Region
8.3.1 Asia-Pacific Sickle Cell Disease Treatment Revenue by Region (2016-2026)
8.3.2 China Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8.3.5 India Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Sickle Cell Disease Treatment Revenue by Type (2016-2026)
9.2 South America Sickle Cell Disease Treatment Revenue by Application (2016-2026)
9.3 South America Sickle Cell Disease Treatment Market Size by Country
9.3.1 South America Sickle Cell Disease Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Sickle Cell Disease Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Sickle Cell Disease Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Sickle Cell Disease Treatment Market Size by Country
10.3.1 Middle East & Africa Sickle Cell Disease Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Sickle Cell Disease Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Sickle Cell Disease Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Sickle Cell Disease Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Sickle Cell Disease Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Sickle Cell Disease Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Sickle Cell Disease Treatment Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Sickle Cell Disease Treatment Product and Solutions
Table 9. AstraZeneca Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly Sickle Cell Disease Treatment Product and Solutions
Table 13. Eli Lilly Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis Sickle Cell Disease Treatment Product and Solutions
Table 17. Novartis Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Sickle Cell Disease Treatment Product and Solutions
Table 21. Pfizer Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Baxter Corporate Information, Head Office, and Major Competitors
Table 23. Baxter Major Business
Table 24. Baxter Sickle Cell Disease Treatment Product and Solutions
Table 25. Baxter Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Emmaus Life Sciences Corporate Information, Head Office, and Major Competitors
Table 27. Emmaus Life Sciences Major Business
Table 28. Emmaus Life Sciences Sickle Cell Disease Treatment Product and Solutions
Table 29. Emmaus Life Sciences Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bluebird bio Corporate Information, Head Office, and Major Competitors
Table 31. Bluebird bio Major Business
Table 32. Bluebird bio Sickle Cell Disease Treatment Product and Solutions
Table 33. Bluebird bio Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Blood Therapeutics Corporate Information, Head Office, and Major Competitors
Table 35. Blood Therapeutics Major Business
Table 36. Blood Therapeutics Sickle Cell Disease Treatment Product and Solutions
Table 37. Blood Therapeutics Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sangamo Therapeutics Corporate Information, Head Office, and Major Competitors
Table 39. Sangamo Therapeutics Major Business
Table 40. Sangamo Therapeutics Sickle Cell Disease Treatment Product and Solutions
Table 41. Sangamo Therapeutics Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Acceleron Pharma Corporate Information, Head Office, and Major Competitors
Table 43. Acceleron Pharma Major Business
Table 44. Acceleron Pharma Sickle Cell Disease Treatment Product and Solutions
Table 45. Acceleron Pharma Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Arena Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Arena Pharmaceuticals Major Business
Table 48. Arena Pharmaceuticals Sickle Cell Disease Treatment Product and Solutions
Table 49. Arena Pharmaceuticals Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Alnylam Pharmaceuticals Major Business
Table 52. Alnylam Pharmaceuticals Sickle Cell Disease Treatment Product and Solutions
Table 53. Alnylam Pharmaceuticals Sickle Cell Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Sickle Cell Disease Treatment Revenue (USD Million) by Players (2019-2021)
Table 55. Global Sickle Cell Disease Treatment Revenue Share by Players (2019-2021)
Table 56. Breakdown of Sickle Cell Disease Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Sickle Cell Disease Treatment Players Head Office, Products and Services Provided
Table 58. Sickle Cell Disease Treatment Mergers & Acquisitions in the Past Five Years
Table 59. Sickle Cell Disease Treatment New Entrants and Expansion Plans
Table 60. Global Sickle Cell Disease Treatment Revenue (USD Million) by Type (2016-2021)
Table 61. Global Sickle Cell Disease Treatment Revenue Share by Type (2016-2021)
Table 62. Global Sickle Cell Disease Treatment Revenue Forecast by Type (2021-2026)
Table 63. Global Sickle Cell Disease Treatment Revenue by Application (2016-2021)
Table 64. Global Sickle Cell Disease Treatment Revenue Forecast by Application (2021-2026)
Table 65. North America Sickle Cell Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Sickle Cell Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Sickle Cell Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Sickle Cell Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Sickle Cell Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Sickle Cell Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Sickle Cell Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Sickle Cell Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Sickle Cell Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Sickle Cell Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Sickle Cell Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Sickle Cell Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Sickle Cell Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Sickle Cell Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Sickle Cell Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Sickle Cell Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Sickle Cell Disease Treatment Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Sickle Cell Disease Treatment Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Sickle Cell Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Sickle Cell Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Sickle Cell Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Sickle Cell Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Sickle Cell Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Sickle Cell Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Sickle Cell Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Sickle Cell Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Sickle Cell Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Sickle Cell Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Sickle Cell Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Sickle Cell Disease Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Sickle Cell Disease Treatment Picture
Figure 2. Global Sickle Cell Disease Treatment Revenue Market Share by Type in 2020
Figure 3. Sickle Cell Anemia
Figure 4. Sickle Beta Thalassemia
Figure 5. Sickle Hemoglobin C Disease
Figure 6. Sickle Cell Disease Treatment Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Sickle Cell Disease Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Sickle Cell Disease Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Sickle Cell Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 13. Global Sickle Cell Disease Treatment Revenue Market Share by Region in 2020
Figure 14. North America Sickle Cell Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Sickle Cell Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Sickle Cell Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Sickle Cell Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Sickle Cell Disease Treatment Market Drivers
Figure 19. Sickle Cell Disease Treatment Market Restraints
Figure 20. Sickle Cell Disease Treatment Market Trends
Figure 21. AstraZeneca Recent Developments and Future Plans
Figure 22. Eli Lilly Recent Developments and Future Plans
Figure 23. Novartis Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Baxter Recent Developments and Future Plans
Figure 26. Emmaus Life Sciences Recent Developments and Future Plans
Figure 27. Bluebird bio Recent Developments and Future Plans
Figure 28. Blood Therapeutics Recent Developments and Future Plans
Figure 29. Sangamo Therapeutics Recent Developments and Future Plans
Figure 30. Acceleron Pharma Recent Developments and Future Plans
Figure 31. Arena Pharmaceuticals Recent Developments and Future Plans
Figure 32. Alnylam Pharmaceuticals Recent Developments and Future Plans
Figure 34. Global Sickle Cell Disease Treatment Revenue Share by Players in 2020
Figure 35. Sickle Cell Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Sickle Cell Disease Treatment Revenue Market Share in 2020
Figure 37. Global Top 10 Players Sickle Cell Disease Treatment Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Sickle Cell Disease Treatment Revenue Share by Type in 2020
Figure 40. Global Sickle Cell Disease Treatment Market Share Forecast by Type (2021-2026)
Figure 41. Global Sickle Cell Disease Treatment Revenue Share by Application in 2020
Figure 42. Global Sickle Cell Disease Treatment Market Share Forecast by Application (2021-2026)
Figure 43. North America Sickle Cell Disease Treatment Sales Market Share by Type (2016-2026)
Figure 44. North America Sickle Cell Disease Treatment Sales Market Share by Application (2016-2026)
Figure 45. North America Sickle Cell Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 46. United States Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Sickle Cell Disease Treatment Sales Market Share by Type (2016-2026)
Figure 50. Europe Sickle Cell Disease Treatment Sales Market Share by Application (2016-2026)
Figure 51. Europe Sickle Cell Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 52. Germany Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Sickle Cell Disease Treatment Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Sickle Cell Disease Treatment Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Sickle Cell Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 60. China Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Sickle Cell Disease Treatment Sales Market Share by Type (2016-2026)
Figure 67. South America Sickle Cell Disease Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America Sickle Cell Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Sickle Cell Disease Treatment Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Sickle Cell Disease Treatment Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Sickle Cell Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Sickle Cell Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の鎌状赤血球症治療市場規模・現状・予測（2021年-2027年） Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorderhave atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape…- 世界の鎌状赤血球症治療市場規模・現状・予測（2021年-2027年） Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents. The care of people with sickle cell disease may include infection prevention with vaccination and antibiotics, high fluid intake, folic acid supplementation and pain medication. Market Analysis and I…
- 世界の鎌状赤血球市場規模・現状・予測（2021年-2027年） The global sickle cell market is expected to grow in future due to rising African-American population, economic growth, increasing healthcare expenditure and prevalence of sickle cell. Key trends of this market include progressing drug pipeline and rising research grants. However, there are some fac…
- 世界の鎌状赤血球貧血治療薬市場規模・現状・予測（2021年-2027年） Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglo…
- 世界の鎌状赤血球貧血治療薬市場規模・現状・予測（2021年-2027年） Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglo…